# Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults

> **NCT00439959** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepatitis C

## Interventions

- **DRUG:** GSK625433/placebo

## Key facts

- **NCT ID:** NCT00439959
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-10
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439959, "Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00439959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*